KR950016740A - 조직의 불완전한 회복을 저해하는 방법 - Google Patents

조직의 불완전한 회복을 저해하는 방법 Download PDF

Info

Publication number
KR950016740A
KR950016740A KR1019940034931A KR19940034931A KR950016740A KR 950016740 A KR950016740 A KR 950016740A KR 1019940034931 A KR1019940034931 A KR 1019940034931A KR 19940034931 A KR19940034931 A KR 19940034931A KR 950016740 A KR950016740 A KR 950016740A
Authority
KR
South Korea
Prior art keywords
compound
formula
tissue
pyrrolidino
piperidino
Prior art date
Application number
KR1019940034931A
Other languages
English (en)
Inventor
프랭크 부몰 토마스
조셉 컬리난 죠지
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950016740A publication Critical patent/KR950016740A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

본 발명은 효과량의 하기 일반식( I )의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물을 조직의 불완전한 회복 또는 적어도 부분적으로 그로 인한 생리학적 질환의 저해를 필요로 하는 인간에게 투여함을 포함하는, 상기 질환의 저해방법을 포함한다:
상기식에서,
Rl및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 그룹중에서 선택된다.

Description

조직의 불완전한 회복을 저해하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 조직의 불완전한 회복을 저해하는데 사용하기 위한 하기 일반식( I )의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  2. 제1항에 있어서, 상기 화합물이 그의 염산 염인 화합물.
  3. 제1항에 있어서, 예방목적으로 투여하는 화합물.
  4. 제1항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물.
  5. 조직의 불완전한 회복과 관련된 생리학적 질환을 저해하는데 사용하기 위한 하기 일반식( I )의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    R1및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  6. 제5항에 있어서, 상기 화합물이 그의 염산 염인 화합물.
  7. 제5항에 있어서, 예방목적으로 투여하는 화합물.
  8. 제5항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물.
  9. 다양한 조직 및 기관의 불완전한 회욕을 개시하는 것으로 공지되고 감염증, 화학 또는 독성 발작, 종양, 대사 질환, 유전가족성 질환, 다중계 질환, 심혈관발적중에서 선택된 질환 또는 상태의 증후군 또는 병리학적 후유중(합병증)을 치료하는데 사용하기 위한 하기 일반식(Ⅰ)의 화합물, 또는 그의 약학적으로 허용가능한 염 또는 용매화물:
    상기식에서,
    Rl및 R3는 독립적으로 수소,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
  10. 제9항에 있어서, 상기 화합물이 그의 염산 염인 화합물.
  11. 제9항에 있어서, 예방목적으로 투여하는 화합물.
  12. 제9항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940034931A 1993-12-21 1994-12-19 조직의 불완전한 회복을 저해하는 방법 KR950016740A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/171,150 1993-12-21
US08/171,150 US5574047A (en) 1993-12-21 1993-12-21 Methods of inhibiting imperfect tissue repair

Publications (1)

Publication Number Publication Date
KR950016740A true KR950016740A (ko) 1995-07-20

Family

ID=22622741

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940034931A KR950016740A (ko) 1993-12-21 1994-12-19 조직의 불완전한 회복을 저해하는 방법

Country Status (17)

Country Link
US (2) US5574047A (ko)
EP (1) EP0664122A1 (ko)
JP (1) JPH07215862A (ko)
KR (1) KR950016740A (ko)
CN (1) CN1051921C (ko)
AU (1) AU690596B2 (ko)
CA (1) CA2138454A1 (ko)
CZ (1) CZ287766B6 (ko)
HU (1) HUT71343A (ko)
IL (1) IL112043A (ko)
NO (1) NO313487B1 (ko)
NZ (1) NZ270180A (ko)
PH (1) PH31324A (ko)
RU (1) RU2133121C1 (ko)
TW (1) TW321600B (ko)
UA (1) UA37212C2 (ko)
ZA (1) ZA9410089B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1996040098A2 (en) 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5496828A (en) * 1994-08-22 1996-03-05 Eli Lilly And Company Methods of inhibiting ulcerative mucositis
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
HUP9801829A3 (en) * 1995-02-06 1999-10-28 Lilly Co Eli Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
US5670523A (en) * 1996-01-29 1997-09-23 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
ID15917A (id) * 1996-01-29 1997-08-21 Lilly Co Eli Metode untuk menghambat tumor usus besar
CZ235398A3 (cs) * 1996-01-29 1999-02-17 Eli Lilly And Company Farmaceutický prostředek pro inhibici muskuloaponeurotických fibromatóz savců zvláště lidí
US6063575A (en) * 1997-03-21 2000-05-16 University Of Maryland, At Baltimore Assay for measuring the activity and fidelity of DNA replication and kit therefor
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
KR20010015672A (ko) * 1997-09-29 2001-02-26 유니버시티 오브 메릴랜드, 볼티모어 악성의 생체표지로서의 변형된 ｄｎａ 신테좀 성분
WO1999016469A1 (en) * 1997-09-29 1999-04-08 University Of Maryland, Baltimore Altered dna synthesome components as biomarkers for malignancy
US6093543A (en) * 1998-04-11 2000-07-25 University Of Maryland, Baltimore Method for detecting the presence of malignant cells using a multi-protein DNA replication complex
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
US7449537B2 (en) * 2001-01-29 2008-11-11 Ndsu Research Foundation Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
JP4212036B2 (ja) * 2003-06-19 2009-01-21 ローム株式会社 定電圧発生器

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
WO1994002130A1 (en) * 1992-07-20 1994-02-03 Massachusetts Institute Of Technology Control of wound scar production with calcium antagonists alone or in a combination with a steroid

Also Published As

Publication number Publication date
US5686467A (en) 1997-11-11
CA2138454A1 (en) 1995-06-22
UA37212C2 (uk) 2001-05-15
NO313487B1 (no) 2002-10-14
RU94044490A (ru) 1996-10-20
CN1109330A (zh) 1995-10-04
PH31324A (en) 1998-07-06
RU2133121C1 (ru) 1999-07-20
CZ322394A3 (en) 1995-09-13
TW321600B (ko) 1997-12-01
HU9403674D0 (en) 1995-02-28
NO944922L (no) 1995-06-22
NZ270180A (en) 1997-07-27
US5574047A (en) 1996-11-12
ZA9410089B (en) 1996-06-19
AU690596B2 (en) 1998-04-30
JPH07215862A (ja) 1995-08-15
NO944922D0 (no) 1994-12-19
HUT71343A (en) 1995-11-28
IL112043A (en) 2000-02-29
AU8155794A (en) 1995-06-29
CZ287766B6 (en) 2001-01-17
IL112043A0 (en) 1995-03-15
EP0664122A1 (en) 1995-07-26
CN1051921C (zh) 2000-05-03

Similar Documents

Publication Publication Date Title
KR950016740A (ko) 조직의 불완전한 회복을 저해하는 방법
KR950016744A (ko) 트롬빈을 저해하는 방법
KR970706818A (ko) 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide)
KR950016738A (ko) 알쯔하이머 질병의 억제 방법
KR950016725A (ko) 폐 고혈압성 질병을 억제하는 방법
KR950016746A (ko) 비-펩티드 타키키닌 수용체 길항물질
KR950016731A (ko) 지루 및 좌창의 억제 방법
KR950016732A (ko) 피부 및 질의 위축 억제방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
KR950010892A (ko) 자궁 섬유증 억제 방법
KR950010893A (ko) 자궁내막증 억제 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950010889A (ko) 혈관형성 및 혈관형성성 질병을 억제하는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR950016724A (ko) 폐경기 후 여성의 리비도를 증가시키는 방법
KR950016730A (ko) 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법
KR950016742A (ko) 폐경후 여성의 씨엔에스 질환을 억제하는 방법
KR950010887A (ko) 연골 퇴화 억제 방법
KR950016734A (ko) 성적 조숙증의 억제방법
KR950016729A (ko) 유방 질환의 억제 방법
KR910004191A (ko) 신질환치료제
KR950016735A (ko) 터너 증후군의 억제 방법
KR950016760A (ko) 치질 치료제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application